

• How does the variation in opioid product dosage strength, dosage form, and potency affect this consideration?

4. How should we consider the following characteristics in determining the specifications for any in-home disposal system?

• Whether, or the extent to which, it is apparent that the used disposal system may contain opioids.

• The potential risks associated with accidental exposure to the in-home disposal system (e.g., ingestion, skin/eye exposure, inhalation). Consider difference in risk for adults, children, and pets.

• Use of child-resistant packaging.

• User interface of an in-home disposal system: *i.e.*, does its design support safe and correct use of the system.

• Robustness in light of expected use error: *i.e.*, does the system still work sufficiently well in real world use scenarios, which may include some reasonably anticipated use errors (e.g., overfilling, incorrect water temperature, insufficient shaking).

5. Are there any other specifications FDA should require or characteristics that FDA should consider? Discuss other actions FDA could take in addition to, or in support of, an in-home disposal system REMS requirement to increase safe disposal of unused opioid analgesics.

V. References

The following references marked with an asterisk (*) are on display at the Dockets Management Staff (see **ADDRESSES**) and available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they also are available electronically at <https://www.regulations.gov>. References without asterisks are not on public display at <https://www.regulations.gov> because they have copyright restriction. Some references may be available at the website address, if listed. References without asterisks are available for viewing only at the Dockets Management Staff. FDA has verified the web addresses, as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

- * Substance Abuse and Mental Health Services Administration, “Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health” (HHS Publication No. PEP25–07–007, NSDUH Series H–60), Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration (2025), available at <https://www.samhsa.gov/data/sites/>

[default/files/reports/rpt56287/2024-nsduh-annual-national/2024-nsduh-annual-national-html-071425-edited/2024-nsduh-annual-national.htm](https://www.regulations.gov/default/files/reports/rpt56287/2024-nsduh-annual-national/2024-nsduh-annual-national-html-071425-edited/2024-nsduh-annual-national.htm).

- Mallama, C.A., C. Greene, A.A. Alexandridis, et al., “Patient-Reported Opioid Analgesic Use After Discharge From Surgical Procedures: A Systematic Review,” *Pain Medicine*, vol. 23(1), pp. 22–29, 2022, <https://doi.org/10.1093/pm/pnab244>.
- Bicket, M.C., J.J. Long, P.J. Pronovost, et al., “Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review,” *JAMA Surgery*, vol. 152(11), pp. 1066–1071, 2017, <https://doi.org/10.1001/jamasurg.2017.0831>.
- Collins, C.L., K. England, SW Conrad, et al., “Patient-Reported Duration of Opioid Analgesic Use After Discharge from Surgical Procedures or Other Types of Acute Pain: A Scoping Review,” *Pain Medicine*, vol. 26(9), pp. 503–514, 2025, <https://doi.org/10.1093/pm/pnaf029>.
- Atwood, K., T. Shackelford, W. Lemons, et al., “Post Discharge Opioid Use After Total Hip and Total Knee Arthroplasty,” *Arthroplasty Today*, vol. 7, 2021, pp. 126–129, <https://doi.org/10.1016/j.artd.2020.12.021>.
- * FDA, “Disposal of Unused Medicines: What You Should Know—Learn How to Dispose of Unused or Expired Drugs,” accessed October 31, 2021, available at <https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know>.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–04479 Filed 3–5–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Submission to the Office of Management and Budget (OMB) for Review and Approval; Public Comment Request; Standardized Work Plan Form for Use with Applications to the Bureau of Health Workforce Research and Training Grants and Cooperative Agreements, OMB No. 0906–0049—Revision

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to OMB.

Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.

DATES: Comments on this ICR should be received no later than May 5, 2026.

ADDRESSES: Submit your comments to paperwork@hrsa.gov or mail the HRSA Information Collection Clearance Officer, Room 13N82, 5600 Fishers Lane, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email paperwork@hrsa.gov or call Samantha Miller, the HRSA Information Collection Clearance Officer, at (301) 443–3983. Officer, at paperwork@hrsa.gov or call (301) 443–3983.

SUPPLEMENTARY INFORMATION: When submitting comments or requesting information, please include the ICR title for reference.

Information Collection Request Title: Standardized Work Plan (SWP) Form for Use with Applications to HRSA’s Bureau of Health Workforce (BHW) Research and Training Grants and Cooperative Agreements, OMB No. 0906–0049—Revision

Abstract: HRSA BHW requires applicants for training and research grants and cooperative agreements to submit work plans via the SWP form. Information in the SWP describes the timeframes and progress required during the grant period of performance to address each of the needs detailed in the Purpose and Need section of the application, as required in the Notice of Funding Opportunity announcement. Applicants use the SWP form when they submit their proposals, and award recipients and Project Officers use the SWP information to assist in monitoring progress once HRSA makes the awards. After awards are made, recipients complete a Quarterly Progress Update (QPU) to provide information to BHW on a quarterly basis on each activity listed in the SWP.

Need and Proposed Use of the Information: The QPU is completed via HRSA’s Electronic Handbook system and prompts recipients to report on progress of activities that were submitted using the SWP in the original application. The QPU automatically populates activities from the recipient’s SWP form on a quarterly basis. For each activity listed in the submitted SWP for any particular quarter within the project period, recipients select and submit a single selection response for each activity status from a pull-down menu with five options: (1) Activity is on

Schedule, (2) Activity is Complete, (3) Timing is off track, (4) Activity will be missed if action is not taken, and (5) Activity cannot be achieved. This information collection request seeks to split “Timing is Off Track” into three options; (1) Timing is Off Track: Barrier Resolved/Proceeding, (2) Activity no longer needed/applicable, and (3) Barrier Not Resolved.

Information provided is utilized by the program staff to regularly assess overall progress of program requirements and analyze data in order to monitor award recipient compliance and track progress against proposed targets and goals. Information gathered allows an improved and more efficient method for identifying whether projects’

goals are being advanced or achieved, as set forth in 2 CFR 200.329. Program staff also use information provided over the period of performance to see emerging trends and to assess whether an award recipient requires technical assistance to address challenges that the award recipient may be experiencing with the implementation of the project. Seeking OMB approval of this revision comports with the regulatory requirement imposed by 2 CFR 200.207(a) and 200.329(b).

Likely Respondents: Respondents are applicants for, and recipients of, BHW’s research and training grants and cooperative agreements.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain,

disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

Total Estimated Annualized Burden Hours:

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total annual burden hours
Standardized Work Plan (SWP)	1,000	1	1,000	1.00	1,000
Quarterly Progress Update (QPU) Form	1,000	4	4,000	0.10	400
Total	1,000	5,000	1,400

¹ The 1,000 SWP respondents reflect the number of new grant applications submitted annually. The 1,000 QPU respondents reflect the current volume of funded, active grants.

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2026-04493 Filed 3-5-26; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, Fellowship: K-Awards March 10, 2026, 10:00 a.m. to March 11, 2026, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on February 06, 2026, 91 FR 5503, Doc No. 2026-02434.

This meeting is being amended to change the end date to 3/10/2026. The meeting is closed to the public.

Dated: March 3, 2026.

Margaret Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-04438 Filed 3-5-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Interdisciplinary Molecular Sciences and Training Integrated Review Group; Advancing Therapeutics—B Study Section.

Date: April 8–9, 2026.

Time: 9:30 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Lystranne Alysia Maynard Smith, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-402-4809, lystranne.maynard-smith@nih.gov.

Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Biochemistry and Biophysics of Membranes Study Section.

Date: April 8–9, 2026.

Time: 9:30 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Irina V. Nesmelova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-6496, irina.nesmelova@nih.gov.

Name of Committee: Center for Scientific Review, Special Emphasis Panel; PAR Panel: SuRE and SuRE-First Programs (R16).

Date: April 8, 2026.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: David R. Filpula, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD